Compare · CCEL vs PGNY
CCEL vs PGNY
Side-by-side comparison of Cryo-Cell International Inc. (CCEL) and Progyny Inc. (PGNY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CCEL and PGNY operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- PGNY is the larger of the two at $2.14B, about 25.6x CCEL ($83.3M).
- Over the past year, CCEL is down 5.7% and PGNY is up 25.9% - PGNY leads by 31.6 points.
- PGNY has been more active in the news (5 items in the past 4 weeks vs 3 for CCEL).
- PGNY has more recent analyst coverage (25 ratings vs 0 for CCEL).
- Company
- Cryo-Cell International Inc.
- Progyny Inc.
- Price
- $4.15-1.89%
- $26.88-2.06%
- Market cap
- $83.3M
- $2.14B
- 1M return
- -6.11%
- -0.43%
- 1Y return
- -5.68%
- +25.94%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 2019
- News (4w)
- 3
- 5
- Recent ratings
- 0
- 25
Cryo-Cell International Inc.
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, kidney, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Progyny Inc.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Latest CCEL
- SEC Form DEF 14A filed by Cryo-Cell International Inc.
- SEC Form 10-Q filed by Cryo-Cell International Inc.
- Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2026 Financial Results
- SEC Form 8-K filed by Cryo-Cell International Inc.
- Chairman, Co-CEO Portnoy David acquired $799,995 worth of shares (600,191 units at $1.33) and disposed of $799,995 worth of shares (600,191 units at $1.33), decreasing direct ownership by 71% to 247,438 units (SEC Form 4)
- SEC Form 10-Q filed by Cryo-Cell International Inc.
- Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2026 Financial Results
- VP Finance, CFO Taymans Jill M exercised 7,500 shares at a strike of $3.10, increasing direct ownership by 17% to 52,896 units (SEC Form 4)
- Cryo-Cell International Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American
Latest PGNY
- SEC Form 4 filed by Progyny Inc.
- Progyny to Present New Menopause Research at The Menopause Society 2026 Annual Meeting
- Progyny, Inc. Selling Season Pacing to Record Level, Revealing Critical Insights on Latest Market Dynamics
- EVP, GC Swartz Allison sold $101,868 worth of shares (3,903 units at $26.10) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 75,816 units (SEC Form 4)
- Chief Product Officer Clapp Geoffrey covered exercise/tax liability with 819 shares, decreasing direct ownership by 1% to 59,009 units (SEC Form 4) to cover taxes
- Amendment: Director Gordon Kevin K exercised 22,000 shares at a strike of $13.00, covered exercise/tax liability with 10,500 shares and sold $311,858 worth of shares (11,500 units at $27.12) (SEC Form 4)
- Director Gordon Kevin K exercised 22,000 shares at a strike of $13.00, covered exercise/tax liability with 10,500 shares and sold $321,358 worth of shares (11,500 units at $27.94) (SEC Form 4)
- SEC Form 144 filed by Progyny Inc.
- CHIEF EXECUTIVE OFFICER Anevski Peter covered exercise/tax liability with 5,361 shares, decreasing direct ownership by 0.66% to 806,111 units (SEC Form 4) to satisfy tax liability
- EVP, GC Swartz Allison covered exercise/tax liability with 1,307 shares, decreasing direct ownership by 2% to 79,719 units (SEC Form 4) (withholding tax)